Clinical Trials
11 trialsNCT06284122 2026-06-05
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT06943872 2026-06-04
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT06084936 2026-06-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06191744 2026-06-02
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT05929222 2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT06073821 2026-06-01
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT03701282 2026-05-29
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-05-29
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05100862 2026-05-27
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT04269902 2026-05-19
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05057494 2026-05-19
MAJIC
AstraZeneca
Phase 3 Active not recruiting